XML Financial LLC acquired a new position in shares of Kenvue Inc. (NYSE:KVUE - Free Report) during the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund acquired 27,650 shares of the company's stock, valued at approximately $640,000.
Several other institutional investors and hedge funds have also recently bought and sold shares of the stock. Leo Wealth LLC grew its position in Kenvue by 0.3% during the third quarter. Leo Wealth LLC now owns 151,611 shares of the company's stock valued at $3,507,000 after purchasing an additional 481 shares in the last quarter. Massmutual Trust Co. FSB ADV increased its holdings in Kenvue by 6.2% in the third quarter. Massmutual Trust Co. FSB ADV now owns 8,400 shares of the company's stock worth $194,000 after buying an additional 492 shares during the last quarter. Wolff Wiese Magana LLC grew its position in Kenvue by 0.7% in the third quarter. Wolff Wiese Magana LLC now owns 76,999 shares of the company's stock worth $1,781,000 after acquiring an additional 501 shares in the last quarter. Marathon Capital Management increased its stake in shares of Kenvue by 0.3% during the 2nd quarter. Marathon Capital Management now owns 149,699 shares of the company's stock worth $2,722,000 after purchasing an additional 514 shares during the last quarter. Finally, Poehling Capital Management INC. raised its holdings in shares of Kenvue by 0.5% during the 2nd quarter. Poehling Capital Management INC. now owns 104,934 shares of the company's stock valued at $1,908,000 after purchasing an additional 547 shares in the last quarter. Institutional investors and hedge funds own 97.64% of the company's stock.
Analyst Ratings Changes
Several equities analysts have weighed in on KVUE shares. UBS Group raised their target price on Kenvue from $20.00 to $22.00 and gave the company a "neutral" rating in a report on Wednesday, August 7th. Royal Bank of Canada lowered Kenvue from an "outperform" rating to a "sector perform" rating and set a $24.00 target price for the company. in a report on Tuesday, September 24th. Deutsche Bank Aktiengesellschaft increased their price target on Kenvue from $23.00 to $24.00 and gave the company a "buy" rating in a report on Wednesday, August 7th. Bank of America boosted their price objective on shares of Kenvue from $24.00 to $27.00 and gave the stock a "buy" rating in a research note on Tuesday, October 22nd. Finally, JPMorgan Chase & Co. lifted their target price on shares of Kenvue from $24.00 to $25.00 and gave the stock an "overweight" rating in a report on Friday, October 11th. One research analyst has rated the stock with a sell rating, seven have given a hold rating and four have given a buy rating to the company. Based on data from MarketBeat.com, Kenvue has a consensus rating of "Hold" and a consensus target price of $22.64.
Check Out Our Latest Analysis on KVUE
Kenvue Stock Performance
Shares of KVUE traded up $0.10 during trading hours on Monday, hitting $23.78. The company had a trading volume of 13,837,465 shares, compared to its average volume of 18,122,139. The firm has a market cap of $45.54 billion, a price-to-earnings ratio of 43.27, a PEG ratio of 3.10 and a beta of 1.36. The company has a quick ratio of 0.68, a current ratio of 0.99 and a debt-to-equity ratio of 0.69. The business has a fifty day moving average of $22.65 and a 200-day moving average of $20.55. Kenvue Inc. has a 12 month low of $17.67 and a 12 month high of $23.88.
Kenvue (NYSE:KVUE - Get Free Report) last posted its earnings results on Thursday, November 7th. The company reported $0.28 earnings per share for the quarter, topping analysts' consensus estimates of $0.27 by $0.01. Kenvue had a return on equity of 21.41% and a net margin of 6.88%. The company had revenue of $3.90 billion during the quarter, compared to the consensus estimate of $3.92 billion. During the same quarter last year, the firm earned $0.31 earnings per share. The company's revenue was down .4% on a year-over-year basis. Equities analysts anticipate that Kenvue Inc. will post 1.07 EPS for the current fiscal year.
Kenvue Announces Dividend
The firm also recently disclosed a quarterly dividend, which will be paid on Wednesday, November 27th. Investors of record on Wednesday, November 13th will be given a dividend of $0.205 per share. The ex-dividend date is Wednesday, November 13th. This represents a $0.82 annualized dividend and a dividend yield of 3.45%. Kenvue's dividend payout ratio is currently 149.09%.
Kenvue Profile
(
Free Report)
Kenvue Inc operates as a consumer health company worldwide. The company operates through three segments: Self Care, Skin Health and Beauty, and Essential Health. The Self Care segment offers cough, cold and allergy, pain care, digestive health, smoking cessation, eye care, and other products under the Tylenol, Motrin, Benadryl, Nicorette, Zarbee's, ORSLTM, Rhinocort, Calpol, and Zyrtec brands.
Further Reading
Before you consider Kenvue, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Kenvue wasn't on the list.
While Kenvue currently has a "Hold" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Thinking about investing in Meta, Roblox, or Unity? Click the link to learn what streetwise investors need to know about the metaverse and public markets before making an investment.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
